Monobody adapter for functional antibody display on nanoparticles for adaptable targeted delivery applications

C. Albert, L. Bracaglia, A. Koide, J. DiRito, T. Lysyy, L. Harkins, C. Edwards, O. Richfield, J. Grundler, K. Zhou, E. Denbaum, G. Ketavarapu, T. Hattori, S. Perincheri, J. Langford, A. Feizi, D. Haakinson, S. A. Hosgood, M. L. Nicholson, J. S. Pober, W. M. Saltzman, S. Koide () and G. T. Tietjen ()
Additional contact information
C. Albert: Yale University
L. Bracaglia: Yale University
A. Koide: New York University Langone Medical Center
J. DiRito: Yale University
T. Lysyy: Yale University
L. Harkins: Yale University
C. Edwards: Yale University
O. Richfield: Yale University
J. Grundler: Yale University
K. Zhou: Yale University
E. Denbaum: New York University Langone Medical Center
G. Ketavarapu: New York University Langone Medical Center
T. Hattori: New York University Langone Medical Center
S. Perincheri: Yale University
J. Langford: Yale University
A. Feizi: Yale University
D. Haakinson: Yale University
S. A. Hosgood: University of Cambridge
M. L. Nicholson: University of Cambridge
J. S. Pober: Yale University
W. M. Saltzman: Yale University
S. Koide: New York University Langone Medical Center
G. T. Tietjen: Yale University

Nature Communications, 2022, vol. 13, issue 1, 1-13

Abstract: Abstract Vascular endothelial cells (ECs) play a central role in the pathophysiology of many diseases. The use of targeted nanoparticles (NPs) to deliver therapeutics to ECs could dramatically improve efficacy by providing elevated and sustained intracellular drug levels. However, achieving sufficient levels of NP targeting in human settings remains elusive. Here, we overcome this barrier by engineering a monobody adapter that presents antibodies on the NP surface in a manner that fully preserves their antigen-binding function. This system improves targeting efficacy in cultured ECs under flow by >1000-fold over conventional antibody immobilization using amine coupling and enables robust delivery of NPs to the ECs of human kidneys undergoing ex vivo perfusion, a clinical setting used for organ transplant. Our monobody adapter also enables a simple plug-and-play capacity that facilitates the evaluation of a diverse array of targeted NPs. This technology has the potential to simplify and possibly accelerate both the development and clinical translation of EC-targeted nanomedicines.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (3)

Downloads: (external link)
https://www.nature.com/articles/s41467-022-33490-8 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-33490-8

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-33490-8

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().